SOTIO Biotech, Biocytogen Ink Research and License Agreement to Develop Next-Generation Antibody-Drug Conjugates
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.
October 26, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
